Spike Protein Impairs Mitochondrial Function in Human Cardiomyocytes: Mechanisms Underlying Cardiac Injury in COVID-19

Cells, Journal Year: 2023, Volume and Issue: 12(6), P. 877 - 877

Published: March 11, 2023

COVID-19 has a major impact on cardiovascular diseases and may lead to myocarditis or cardiac failure. The clove-like spike (S) protein of SARS-CoV-2 facilitates its transmission pathogenesis. Cardiac mitochondria produce energy for key heart functions. We hypothesized that S1 would directly impair the functions cardiomyocyte mitochondria, thus causing dysfunction.

Language: Английский

---

Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues

Autoimmunity, Journal Year: 2023, Volume and Issue: 56(1)

Published: Sept. 14, 2023

As a result of the spread SARS-CoV-2, global pandemic was declared. Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people with minimal danger suffering serious complications due COVID-19. Solid immuno-histopathological evidence demonstrates that genetic vaccines can display wide distribution within body, affecting tissues are terminally differentiated far away from injection site. These heart brain, which may incur in situ production spike protein eliciting strong autoimmunological inflammatory response. Due fact every human cell synthesises non-self antigens, inevitably becomes target system, since body is not strictly compartmentalised accurate pharmacokinetic pharmacodynamic studies needed order determine precisely be harmed. Therefore, our article aims draw attention scientific regulatory communities critical need for biodistribution against COVID-19, as well rational harm-benefit assessments by group.

Language: Английский

---

Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems

Vaccines, Journal Year: 2024, Volume and Issue: 12(8), P. 873 - 873

Published: Aug. 1, 2024

mRNA vaccines are leading a medical revolution. technologies utilize the host's own cells as bio-factories to produce proteins that serve antigens. This revolutionary approach circumvents complicated processes involved in traditional vaccine production and empowers with ability respond emerging or mutated infectious diseases rapidly. Additionally, robust cellular immune response elicited by has shown significant promise cancer treatment. However, inherent instability of complexity tumor immunity have limited its broader application. Although emergence pseudouridine ionizable cationic lipid nanoparticles (LNPs) made clinical application possible, there remains substantial potential for further improvement immunogenicity delivered antigens preventive therapeutic effects technology. Here, we review latest advancements vaccines, including but not target selection delivery systems. offers multifaceted perspective on this rapidly evolving field.

Language: Английский

---

Assessing the impact of mRNA vaccination in chronic inflammatory murine model

npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)

Published: Feb. 15, 2024

Abstract The implications of administration mRNA vaccines to individuals with chronic inflammatory diseases, including myocarditis, rheumatoid arthritis (RA), and bowel disease (IBD), are unclear. We investigated vaccine effects in a inflammation mouse model implanted an LPS pump, focusing on toxicity immunogenicity. Under inflammation, exacerbated cardiac damage inducing mild heart heightened pro-inflammatory cytokine production cell infiltration the heart. Concurrently, significant muscle occurred, disturbances mitochondrial fusion fission factors signaling impaired repair. However, did not adversely affect muscles at vaccination site or humoral immune responses; nevertheless, it partially reduced cell-mediated response, particularly T-cell activation. These findings underscore importance addressing immunogenicity context ensuring their safe effective utilization, among vulnerable populations immune-mediated diseases.

Language: Английский

---

Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(8), P. 4522 - 4522

Published: April 20, 2024

Here, we target the high-density lipoprotein (HDL) proteome in a case series of 16 patients with post-COVID-19 symptoms treated HMG-Co-A reductase inhibitors (statin) plus angiotensin II type 1 receptor blockers (ARBs) for 6 weeks. Patients suffering from persistent (post-acute sequelae) after serologically confirmed SARS-CoV-2 infection (post-COVID-19 syndrome, PCS, n = 8) or following vaccination (PVS, were included. Asymptomatic subjects corresponding serological findings served as healthy controls (n 8/8). HDL was isolated using dextran sulfate precipitation and all study participants analyzed quantitatively by mass spectrometry. Clinical assessed questionnaires before therapy. The inflammatory potential patients’ addressed human endothelial cells. PCS PVS showed no significant differences; however, compared to controls, PVS/PCS displayed alterations involving hemoglobin, cytoskeletal proteins (MYL6, TLN1, PARVB, TPM4, FLNA), amyloid precursor protein. Gene Ontology Biological Process (GOBP) enrichment analysis identified hemostasis, peptidase, regulation pathways be involved. Treatment statins ARBs improved clinical symptoms. After therapy, three significantly increased (FAM3C, AT6AP2, ADAM10; FDR < 0.05) PVS/PCS. Exposure cells revealed reduced cytokine adhesion molecule expression. Thus, enables deeper insight into underlying disease mechanisms, pointing involvement metabolic signaling disturbances. proteome. These observations may guide future therapeutic strategies patients.

Language: Английский

---